Abstract:BACKGROUND:The benefit of induction chemotherapy in locally advanced oral squamous cell carcinoma (OSCC) remains to be clearly defined. Induction chemotherapy is likely to be effective for biologically distinct subgroups of patients and biomarker development might lead to identification of the patients whose tumors are to respond to a particular treatment. Annexin A1 may serve as a biomarker for responsiveness to induction chemotherapy. The aim of this study was to investigate Annexin A1 expression in pre-treatment biopsies from a cohort of OSCC patients treated with surgery and post-operative radiotherapy or docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy followed by surgery and post-operative radiotherapy. Furthermore we sought to assess the utility of Annexin A1 as a prognostic or predictive biomarker.METHODS:Immunohistochemical staining for Annexin A1 was performed in pre-treatment biopsies from 232 of 256 clinical stage III/IVA OSCC patients. Annexin A1 index was estimated as the proportion of tumor cells (low and high, <50% and ≥50% of stained cells, respectively) to Annexin A1 cellular membrane and cytoplasm staining.RESULTS:There was a significant correlation between Annexin A1 expression and pathologic differentiation grade (P=0.015) in OSCC patients. The proportion of patients with low Annexin A1 expression was significantly higher amongst those with moderate/poorly differentiated tumor (78/167) compared to those with well differentiated tumor (18/65). Multivariate Cox model analysis showed clinical stage (P=0.001) and Annexin A1 expression (P=0.038) as independent prognostic risk factors. Furthermore, a low Annexin A1 expression level was predictive of longer disease-free survival (P=0.036, HR=0.620) and locoregional recurrence-free survival (P=0.031, HR=0.607) compared to high Annexin A1 expression. Patients with moderate/poorly differentiated tumor and low Annexin A1 expression benefited from TPF induction chemotherapy as measured by distant metastasis-free survival (P=0.048, HR=0.373) as well as overall survival (P=0.078, HR=0.410).CONCLUSIONS:Annexin A1 can be used as a prognostic biomarker for OSCC. Patients with moderate/poorly differentiated OSCC and low Annexin A1 expression can benefit from the addition of TPF induction chemotherapy to surgery and post-operative radiotherapy. Annexin A1 expression can potentially be used as a predictive biomarker to select OSCC patients with moderate/poorly differentiated tumor who may benefit from TPF induction chemotherapy.

Cyclin D1 Overexpression Enhances Chemosensitivity to TPF Chemotherapeutic Agents Via the Caspase-3 Pathway in Oral Cancer

Cyclin D1 as a potential predictive biomarker for TPF induction chemotherapy in cN2 patients with oral squamous cell carcinoma

Elevated Growth Differentiating Factor 15 Expression Predicts Long-Term Benefit of Docetaxel, Cisplatin and 5-Fluorouracil Induction Chemotherapy in Patients with Oral Cancer

Inhibition of Cyclin D1 Expression by Cyclin D1 Shrnas in Human Oral Squamous Cell Carcinoma Cells is Associated with Increased Cisplatin Chemosensitivity.

Long-Term Results of A Randomized Phase Iii Trial of Tpf Induction Chemotherapy Followed by Surgery and Radiation in Locally Advanced Oral Squamous Cell Carcinoma

GDF15 is a Potential Predictive Biomarker for TPF Induction Chemotherapy and Promotes Tumorigenesis and Progression in Oral Squamous Cell Carcinoma

Supplementary Tables 1 - 5 from Elevated Cyclin D1 Expression is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease

Supplementary Figure 1 from Elevated Cyclin D1 Expression is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease

Mechanism of Sensitivity to TPF Chemoagents and Its Potential Alternative of Erbb2 in Oral Cancer with GDF15 Overexpression.

High Ki67 Expression Before Docetaxel, Cisplatin, and Fluorouracil (TPF) Neoadjuvant Chemotherapy Predicts Better Prognosis in Patients with Locally Advanced Oral Squamous Cell Carcinoma

Personalized TPF Induction Chemotherapy on the Basis of Stathmin Expression in Patients with Locally Advanced Oral Squamous Cell Carcinoma.

Mechanism of sensitivity to cisplatin, docetaxel, and 5‐fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression

TPF Induction Chemotherapy and Pathologic Response for Patients with Locally Advanced and Resectable Oral Squamous Cell Carcinoma.

Relationship of Low Stathmin Expression and Benefit from TPF Induction Chemotherapy and Its Role in Chemoresistance Via Mutant P53 in Oral Cancer.

Overexpression of Stathmin 1 Leads to Docetaxel Based Induction Chemotherapy Resistance Via Mutant P53 in Oral Squamous Cell Carcinoma

Decreased Annexin A1 Expression Enhances Sensitivity to Docetaxel, Cisplatin and 5-Fluorouracil Combination Induction Chemotherapy in Oral Squamous Cell Carcinoma

Cyclin D1 Overexpression is Associated with Poor Clinicopathological Outcome and Survival in Oral Squamous Cell Carcinoma in Asian Populations: Insights from a Meta-Analysis

Overexpression of Cyclin B1 Antagonizes Chemotherapeutic-Induced Apoptosis Through Pten/Akt Pathway in Human Esophageal Squamous Cell Carcinoma Cells

Effects of Cyclin D1 Antisense Oligodeoxyneucleotides on Chemosensitivity of Gastric Carcinoma Cells

Low Annexin A1 Expression Predicts Benefit from Induction Chemotherapy in Oral Cancer Patients with Moderate or Poor Pathologic Differentiation Grade

Cyclin G2 Inhibits Oral Squamous Cell Carcinoma Growth and Metastasis by Binding to IGFBP3 and Regulating the FAK-SRC-STAT Signaling Pathway